|
|
Profile
|
Delegates :
Takashi Ono |
|
Incorporated :
May 15 , 2015 |
Paid in Capital :
753 Million yen We receive an investments from KISCO Ltd., The University of Tokyo Edge Capital Co. Ltd., and QB Capital LLC |
Employees :
28 人 |
Address :
Fukuoka Tenjin Fukoku Seimei Bldg.,4th Fl. 1-9-17 Tenjin,Chuo-ku,Fukuoka-shi, FUKUOKA
〒8100001
|
TEL/FAX :
+81-92-802-4935 / +81-92-802-4934 |
URL：
https://www.editforce.jp |
Attachment :
 JBA登録用画像（英語版）.pdf [ 163.6KiB ] |
Mission/Background :
●EditForce Inc. is based on DNA/RNA manipulation tools using PPR (Pentatrico Peptide Repeat) protein engineering technology found by Associate Professor Takahiro Nakamura of Kyushu University Agricultural Research Institute. We aim to establish for the spread of PPR technology and practical application in a wide range of fields as a venture company from Kyushu University.
●Our PPR technology is the world's first technology in the sense that enables to manipulate both DNA and RNA.
●With the vision of "New Tools Lead to a New World", we promote for technology development so that world's first and from Japan PPR technology will become a new global standard. We will contribute to the development of the bio-industry by applying PPR technology to a wide range of fields such as medicine, chemical industry and agriculture. |
|
Technology & Business
|
【Technology】
Our core technology is DNA/RNA manipulating tools using PPR protein. It is possible to sequence-specifically bind to DNA/RNA, and in addition, to freely manipulate the target DNA/RNA by fusing functional modules. With this technology, we contribute to a wide range of biological fields.
【Advantage of service】
Whereas existing genomic editing is confined to DNA editing, our PPR technology has advantages in that it can also manipulate RNA in addition to DNA. This makes it possible to adapt to a wide range of fields as compared with existing genomic editing such as therapeutic approaches to acquired diseases targeting RNA and detection of RNA viruses.
【Public project】
NEDO, JST, OPERA etc.
【intellectual property】
Design and utilization of artificial protein binding to RNA [PCT/JP2012/077274; Kyushu University]
Design and utilization of artificial protein binding to DNA [PCT/JP2014/061329; Kyushu University and Hiroshima University]
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
License Business of DNA/RNA editing technology using PPR protein engineering technology
|
Discovery
|
Provide usage rights of our patented technology
|
We aim to collaborate with joint research etc. with domestic and overseas pharmaceutical companies.
|
Contract manufacturing business of reagents
|
Service/Marketing
|
Design PPR protein based on sequence information of target RNA and provide DNA encoding PPR
|
We aim to expand use in academic research.
|
Development business of new age-related macular degeneration therapeutic drug
|
Discovery
|
Research and development of new age-related macular degeneration therapeutic drug by utilizing PPR technology
|
We aim to improve patient's QOL and have functions that can not be done with existing drugs.
|
|
|
|
|
|
|
|
|
|
Highlights
|
1.Patents
Jun.2016 We have singed license agreement for patents on DNA-PPR technology with Kyushu University and Hiroshima University.
Sep.2016 We have singed license agreement for patents on RNA-PPR technology with Kyushu University.
（For details on patents, see the [Technical & Business] section above）
2.Agreement
Jul.2018 We have signed a joint research contract with Japan innovative drug therapeutics Inc, for the creation of an age-related macular degeneration therapeutic drug.
|
|
Hot news
|
・Mar.2019
EditForce has raised 870 million yen by March 1, 2019, from six new and existing investors in the Series B2 round, as described below.
Investors:
-The University of Tokyo Edge Capital Co., Ltd. (UTEC) -QB Capital, LLC
-Japan Science and Technology Agency (JST)
-Newton Biocapital
-ITOCHU Technology Ventures, Inc.
-K4 Ventures Godo Kaisha (The Kansai Electric Power Group)
|
|
Alliance strategy
|
We hope for alliances with partners who can collaborate research and technology derivation both domestically and internationally.
・Alliance with a pharmaceutical company aiming for creation of drugs and clarification of target molecules / functions
・Alliances with companies interested in DNA/RNA manipulation tools in a wide range of fields such as agriculture and chemical industry as well as medicine.
|
|
|